Rituxan (rituximab) is indicated for the treatment of patients with non-progressing (including stable disease), low-grade, CD20-positive, B-cell Non-Hodgkin Lymphoma, as a single agent, after first-line CVP chemotherapy

INN:

Subtype:

Marginal Zone Lymphoma (MZL)

License:

FDA

Class:

CD20 monoclonal antibody

R/R

PIhttps://www.gene.com/download/pdf/rituxan_prescribing.pdf 

1. Approved Labelling 

Rituxan (rituximab) is indicated for the treatment of patients with non-progressing (including stable disease), low-grade, CD20-positive, B-cell Non-Hodgkin Lymphoma, as a single agent, after first-line CVP chemotherapy.

2. Treatment Regimen 

Premedicate before each infusion. Administer only as an intravenous (IV) infusion.  Following completion of 6−8 cycles of CVP chemotherapy, administer once weekly for 4 doses at 6-month intervals to a maximum of 16 doses.

The recommended dose is 375 mg/m2 as an IV infusion according to the following schedule:

First Infusion: Initiate infusion at a rate of 50 mg/hr. In the absence of infusion toxicity, increase infusion rate by 50 mg/hr increments every 30 minutes, to a maximum of 400 mg/hr.

Subsequent Infusions: Initiate infusion at a rate of 100 mg/hr. In the absence of infusion toxicity, increase rate by 100 mg/hr increments at 30-minute intervals, to a maximum of 400 mg/hr.

Interrupt the infusion or slow the infusion rate for infusion reactions.

3. AE/Warnings

Please see section 5 of the PI.

All content on this site is intended for healthcare professionals only. If you are a patient or carer, please visit the Lymphoma Coalition.